Erratum: Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis (Journal of Clinical Investigation (2003) 112 (152-159) DOI:10.1172/JCI200317740);Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis

Journal of Clinical Investigation

Volumn 112, Issue 2, 2003, Pages 152-159

  Canbay, Ali ^a   Guicciardi, Maria Eugenia ^a   Higuchi, Hajime ^a   Feldstein, Ariel ^a   Bronk, Steven F ^a   Rydzewski, Robert ^b   Taniai, Makiko ^a   Gores, Gregory J ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b CELERA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA CHEMOKINE; CATHEPSIN B; CATHEPSIN B INHIBITOR; COLLAGEN; CYTOCHROME C; ENZYME INHIBITOR; R 3032; UNCLASSIFIED DRUG; BILE ACID; BILIRUBIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT LIGATION; CELL ACTIVATION; CHOLESTASIS; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME INACTIVATION; FIBROGENESIS; HEPATITIS; LIVER FIBROSIS; LIVER INJURY; LYSOSOME; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; STELLATE CELL; TISSUE INJURY; ANIMAL; BLOOD; C57BL MOUSE; DRUG ANTAGONISM; FIBROSIS; IMMUNOBLOTTING; INFLAMMATION; INJURY; LIVER; LIVER CELL; METABOLISM; MITOCHONDRION; MOUSE MUTANT; NEUTROPHIL; NICK END LABELING; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS; BILE ACIDS AND SALTS; BILIRUBIN; CATHEPSIN B; CHOLESTASIS; CYTOCHROME C GROUP; FIBROSIS; HEPATOCYTES; IMMUNOBLOTTING; IN SITU NICK-END LABELING; INFLAMMATION; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; NEUTROPHILS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 0042744006     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317740     Document Type: Erratum

References (35)

1. Kim, W.R., Brown, R.S., Jr., Terrault, N.A., and El-Serag, H. 2002. Burden of liver disease in the United States: summary of a workshop. Hepatology. 36:227-242.
2. Sandler, R.S., et al. 2002. The burden of selected digestive diseases in the United States. Gastroenterology. 122:1500-1511.
3. Galle, P.R., et al. 1995. Involvement of the CD95 (APC)-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1223-1230.
4. Luster, A.D. 1998. Chemokines: chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:436-445.
5. Miwa, K., et al. 1998. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4:1287-1292.
6. Lawson, J.A., Fisher, M.A., Simmons, C.A., Farhood, A., and Jaeschke, H. 1998. Parenchymal cell apoptosis as a signal for sinusoidal sequestration and transendothelial migration of neutrophils in murine models of endotoxin and Fas-antibody-induced liver injury. Hepatology. 28:761-767
7. Jaeschke, H. 2002. Inflammation in response to hepatocellular apoptosis. Hepatology. 35:964-966.
8. Maher, J.J., Scott, M.K., Saito, J.M., and Burton, M.C. 1997. Adenovirus-mediated expression of cytokine-induced neutrophil chemoattractant in rat liver induces a neutrophilic hepatitis. Hepatology. 25:624-630.
9. Leist, M., Gantner, F., Jilg, S., and Wendel, A. 1995. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J. Immunol. 154:1307-1316.
10. Guicciardi, M.E., et al. 2000. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J. Clin. Invest. 106:1127-1137.
11. Faubion, W.A., et al. 1999. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest. 103:137-145.
12. Miyoshi, H., Rust, C., Roberts, P.J., Burgart, L.J., and Gores, G.J. 1999. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology. 117:669-677.
13. Guicciardi, M.E., Miyoshi, H., Bronk, S.F., and Gores, G.J. 2001. Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am. J. Pathol. 159:2045-2054.
14. Roberts, L.R., et al. 1997. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. Gastroenterology. 113:1714-1726.
15. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:481-490.
16. Werneburg, N.W., Guicciardi, M.E., Bronk, S.F., and Gores, G.J. 2002. Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am. J. Physiol. Gastrointest. Liver Physiol. 283:G947-G956.
17. Friedman, S.L. 2000. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275:2247-2250.
18. Canbay, A., et al. 2002. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology. 123:1323-1330.
19. Song, E., et al. 2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9:347-351.
20. Deussing, J., et al. 1998. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc. Natl. Acad. Sci. U. S. A. 95:4516-4521.
21. Sebo, T.J. 1995. Digital image analysis. Mayo Clin. Proc. 70:81-82.
22. Boone, C.W., et al. 2000. Quantitative grading of rat esophageal carcinogenesis using computer-assisted image tile analysis. Cancer Epidemiol. Biomarkers Prev. 9:495-500.
23. Green, D.R., and Reed, J.C. 1998. Mitochondria and apoptosis. Science. 281:1309-1312.
24. Bajt, M.L., Farhood, A., and Jaeschke, H. 2001. Effects of CXC chemokines on neutrophil activation and sequestration in hepatic vasculature. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G1188-G1195.
25. Faouzi, S., et al. 2001. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J. Biol. Chem. 276:49077-49082.
26. Hellerbrand, C., Stefanovic, B., Giordano, F., Burchardt, E.R., and Brenner, D.A. 1999. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J. Hepatol. 30:77-87.
27. Iredale, J.P. 2001. Hepatic stellate cell behavior during resolution of liver injury. Semin. Liver Dis. 21:427-436.
28. Iredale, J.P., et al. 1998. Mechanism of spontaneous resolution of rat liver fibrosis. J. Clin. Invest. 102:538-549.
29. Murphy, F.R., et al. 2002. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem. 277:11069-11076.
30. Roberts, L.R., Adjei, P.N., and Gores, G.J. 1999. Cathepsins as effector proteases in hepatocyte apoptosis. Cell Biochem. Biophys. 30:71-88.
31. Foghsgaard, L., et al. 2001. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol. 153:999-1010.
32. Yuan, X.M., et al. 2002. Lysosomal destabilization in p53-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 99:6286-6291.
33. Jaeschke, H., et al. 2002. Mechanisms of hepatotoxicity. Toxicol. Sci. 65:166-176.
34. Maher, J.J. 2001. Interactions between hepatic stellate cells and the immune system. Semin. Liver Dis. 21:417-426.
35. Canbay, A., et al. 2003. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab. Invest. 83:655-663.